Zai Lab
Michelle Yuan is a seasoned professional with extensive experience in clinical operations and support. Currently serving as a Sr. Clinical Operations Manager at 再鼎医药 since May 2021, Michelle previously held the position of Sr. Clinical Support Manager at Astellas Pharma China, Inc., where responsibilities included leading a clinical support team and managing resources for clinical activities. Prior roles include Global Study Associate Manager at AstraZeneca, Regional Project Manager at Covance, and various positions in clinical trial assistance at GSK and Theorem Clinical Research. Michelle holds a Bachelor of Arts in English from Shanghai University of Sport, obtained in 2009.
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.